White C W, Schwartz J L, Ferguson D W, Brayden G P, Kelly K J, Kioschos J M, Marcus M L
Am J Cardiol. 1984 Oct 1;54(7):712-7. doi: 10.1016/s0002-9149(84)80195-2.
Reasons for the failure of intracoronary streptokinase (STK) to result in coronary thrombolysis were examined in 45 patients with acute myocardial infarction presenting with angiographic evidence of total coronary occlusion. In 25 patients (group A), clot lysis was initially successful; in 20 (group B), reperfusion was unsuccessful. The STK dosage in group A ranged from 84,000 to 310,000 units (mean 188,000 +/- 12,000); STK dosage in group B ranged from 160,000 to 360,000 units (mean 267,000 +/- 11,000 [p less than 0.05]). Before therapy, levels of fibrin degradation products and serum fibrinogen were normal in all patients. After intracoronary STK, fibrin degradation products and serum fibrinogen levels changed similarly in both groups. Eight-five percent of patients in group B had evidence of a systemic fibrinolytic state. These data suggest that higher doses of STK administered in the same manner are unlikely to result in an increased reperfusion rate. Systemic hematologic markers of fibrinolysis are not helpful in explaining the success or failure of intracoronary thrombolysis.
对45例急性心肌梗死且冠状动脉造影显示完全闭塞的患者,研究了冠状动脉内注射链激酶(STK)未能实现冠状动脉溶栓的原因。25例患者(A组)最初溶栓成功;20例(B组)再灌注未成功。A组的STK剂量为84,000至310,000单位(平均188,000±12,000);B组的STK剂量为160,000至360,000单位(平均267,000±11,000 [p<0.05])。治疗前,所有患者的纤维蛋白降解产物和血清纤维蛋白原水平均正常。冠状动脉内注射STK后,两组的纤维蛋白降解产物和血清纤维蛋白原水平变化相似。B组85%的患者有全身纤溶状态的证据。这些数据表明,以相同方式给予更高剂量的STK不太可能提高再灌注率。纤溶的全身血液学标志物无助于解释冠状动脉内溶栓的成功或失败。